Vaxcyte Accelerates VAX-31 into Multiple Phase 3 Trials, Secures Long-Term Manufacturing, and Finalizes $600M Offering
PCVX has more than doubled off its 52-week low of $27.66.
Summary
Vaxcyte is rapidly advancing its lead VAX-31 vaccine into multiple Phase 3 adult trials and completed infant Phase 2 enrollment, while securing long-term manufacturing agreements and finalizing a $600 million public offering to fund its pipeline.
Key Events · Product Development and Regulatory · PCVX
-
VAX-31 Adult Phase 3 Program Expanded
Vaxcyte initiated two additional Phase 3 trials for its VAX-31 adult pneumococcal vaccine candidate in January and February 2026 (OPUS-2 and OPUS-3), building on the pivotal OPUS-1 trial launched in December 2025. Topline data for OPUS-1 is expected in Q4 2026, and for OPUS-2/OPUS-3 in H1 2027.
-
Long-Term Manufacturing Capacity Secured
A new Development and Manufacturing Services Agreement was signed with Lonza on February 18, 2026, for commercial supply of PCV components through 2038. This follows a September 2025 agreement with Thermo Fisher Scientific for up to $1 billion in commercial fill-finish capacity.
-
Successful Public Offering Finalized
The company completed an underwritten public offering in February 2026, issuing 12,650,000 shares at $50.00 per share, generating approximately $600.2 million in net proceeds. This provides substantial capital for ongoing operations and pipeline advancement.
-
VAX-31 Infant Phase 2 Enrollment Completed
Enrollment for the Phase 2 dose-finding study of VAX-31 in healthy infants was completed in January 2026, with topline safety, tolerability, and immunogenicity data anticipated by the end of H1 2027.
Analysis · PCVX · Life Sciences
Vaxcyte, a clinical-stage vaccine company, has significantly advanced its lead pneumococcal conjugate vaccine (PCV) candidate, VAX-31, by initiating two additional Phase 3 trials (OPUS-2 and OPUS-3) in early 2026, following the December 2025 launch of the pivotal OPUS-1 study. This rapid progression into a comprehensive Phase 3 program for adults, coupled with the completion of enrollment for the VAX-31 infant Phase 2 study, underscores the company's commitment to bringing its broad-spectrum vaccine to market. Furthermore, Vaxcyte has bolstered its commercial readiness by entering into a new long-term manufacturing agreement with Lonza and a substantial $1 billion fill-finish capacity commitment with Thermo Fisher. These operational advancements are supported by a recently finalized public offering in February 2026, which raised approximately $600.2 million in net proceeds, providing crucial capital for its extensive development and manufacturing initiatives. While the company reported a significant increase in net loss for 2025, this is typical for a biotech with multiple late-stage clinical programs and is offset by strong financing activities and a projected cash runway of at least 12 months.
At the time of this filing, PCVX was trading at $59.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7B. The 52-week trading range was $27.66 to $83.33. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.